Segment reporting (Tables)

6 Months Ended

Feb. 28, 2023

Segment Reporting [Abstract]

Reconciliation of Operating Income (Loss) from Segments to Consolidated

The following table reflects results of operations of the Company’s reportable segments (in millions):

	Three months ended February 28,				Six months ended February 28,
	2023		2022		2023		2022
Sales:
U.S. Retail Pharmacy	$	27,577	$	27,667	$	54,781	$	55,699
International	5,651		5,563		10,840		11,381
U.S. Healthcare	1,634		527		2,622		577
Corporate and Other	—		(1)		—		(1)
Walgreens Boots Alliance, Inc.	$	34,862	$	33,756	$	68,244	$	67,656
Adjusted operating income (Non-GAAP measure):
U.S. Retail Pharmacy	$	1,067	$	1,588	$	2,172	$	3,277
International	352		226		468		389
U.S. Healthcare	(159)		(77)		(311)		(90)
Corporate and Other	(44)		(79)		(100)		(143)
Walgreens Boots Alliance, Inc.	$	1,215	$	1,657	$	2,229	$	3,434

The following table reconciles adjusted operating income to operating income (loss) (in millions):

	Three months ended February 28,				Six months ended February 28,
	2023		2022		2023		2022
Adjusted operating income (Non-GAAP measure)	$	1,215	$	1,657	$	2,229	$	3,434
Certain legal and regulatory accruals and settlements	(427)		—		(6,981)		—
Acquisition-related amortization	(247)		(250)		(577)		(415)
Acquisition-related costs	(148)		(44)		(187)		(115)
Transformational cost management	(145)		(70)		(283)		(273)
Adjustments to equity earnings in AmerisourceBergen	(31)		(51)		(117)		(94)
LIFO provision	(20)		5		(38)		(9)
Operating income (loss) (GAAP measure)	$	197	$	1,246	$	(5,954)	$	2,529